Jasper Therapeutics, Inc. Stock Analysis & AI Score
Jasper Therapeutics, Inc. (JSPR) has an ST Score of 28.9 (C-), driven by its Forecast (B+) and held back by its Profitability (F). Analysts rate it Buy with a $2.50 price target (+327.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Jasper Therapeutics, Inc. (JSPR) has an ST Score of 28.9 (C-), driven by its Forecast (B+) and held back by its Profitability (F). Analysts rate it Buy with a $2.50 price target (+327.1% upside).
- Strongest
- ForecastB+
- Weakest
- ProfitabilityF
All factor grades
- ForecastB+
- GrowthB
- ValuationC
- MomentumD+
- Financial StrengthD-
- ProfitabilityF
- Piotroski0/9
Contact
JSPR stock: frequently asked questions
What is JSPR's ST Score?
Jasper Therapeutics, Inc. (JSPR) has an ST Score of 28.9 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is JSPR a buy, hold, or sell?
Analysts rate JSPR a Buy, with a price target of $2.50 (+327.1% vs the current price). Our ST Score grades it C- (28.9/100). The ST Score is a data-driven signal, not a recommendation.
What are JSPR's factor grades?
Valuation C, Profitability F, Financial Strength D-, Momentum D+, Growth B, Forecast B+.
What is JSPR's valuation grade?
Jasper Therapeutics, Inc. (JSPR) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is JSPR's growth grade?
Jasper Therapeutics, Inc. (JSPR) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is JSPR's profitability grade?
Jasper Therapeutics, Inc. (JSPR) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is JSPR's financial strength grade?
Jasper Therapeutics, Inc. (JSPR) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for JSPR?
The average analyst price target for Jasper Therapeutics, Inc. (JSPR) is $2.50 from 13 analysts, which is +327.1% versus the recent price of $0.59.
What is JSPR's Piotroski score?
Jasper Therapeutics, Inc. (JSPR) has a Piotroski F-Score of 0 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.